ELAN vs. TAK: Elanco Animal Health vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Elanco Animal Health (ELAN) and Takeda Pharmaceutical (TAK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Elanco Animal Health (ELAN) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Elanco Animal Health (ELAN) has a non-negative beta of 1.65.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Takeda Pharmaceutical (TAK) earns 0.56% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.

Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Takeda Pharmaceutical (TAK) reports 0.87%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) at 24.55% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.

Profitability Metrics

Growth

Elanco Animal Health (ELAN) at 6.22% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Elanco Animal Health (ELAN) at -169.12% is in the bottom quartile, showing a clear gap in earnings momentum.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Takeda Pharmaceutical (TAK) shows current ratio of 1.15 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.

Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Elanco Animal Health (ELAN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Elanco Animal Health (ELAN) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Takeda Pharmaceutical (TAK) trades at 300.29 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.

Both Elanco Animal Health (ELAN) at 2.50 and Takeda Pharmaceutical (TAK) at 0.01 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Elanco Animal Health (ELAN) at 1.95 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics